At Mayo Clinic, metabolomics is a top priority of the Center for Individualized Medicine and its Pharmacogenomics Program, the Center for Regenerative Medicine, and the Mayo Clinic Cancer Center-Research.

The Nuclear Magnetic Resonance Spectroscopy (NMRS) Core is built on the existing metabolomics services and expertise provided by Slobodan I. Macura, Ph.D., principal investigator; the NMR Facility team and Petras P. Dzeja, Ph.D., principal investigator, and the metabolomics group in the Division of Cardiovascular Diseases. These teams have assisted Mayo Clinic investigators with applications of large-scale and stable isotope metabolomic technologies and high-field NMRS to study metabolic systems and metabolic profiling of cell lines, transgenic animals and human diseases for more than 15 years.

The teams use NMRS in vitro and in vivo for metabolic research, metabolite identification, structural analysis, and the introduction of 18O-assisted 31P NMRS and mass spectrometry technology designed for simultaneous measurements of metabolite levels and turnover rates. They developed the Mayo Clinic phosphometabolomics platform (see selected publications), which integrates the Metabolomics NMRS Core and Metabolomics Mass Spectrometry Core and permits the analysis of a large class of phosphometabolites and their turnover rates, quantified using 18O tags introduced by metabolic labeling.


The Metabolomics NMRS Core is located on the subway level and fifth floor of the Stabile Biotechnology Building, at 150 Third Street S.W. in Rochester, Minnesota.

Core co-directors

Petras P. Dzeja, Ph.D. and Slobodan I. Macura, Ph.D. direct the Metabolomics NMRS Core.

Research collaborators

More than 20 National Institutes of Health-supported Mayo Clinic investigators use and benefit from the Metabolomics NMRS Core, including investigators from the Center for Multiple Sclerosis and CNS Demyelinating Diseases.